AZ partners with RenalytixAI in chronic disease pact
AstraZeneca has linked with RenalytixAI to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases.
In the first stage in the partnership, the companies will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to look at further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System.
The goal of this is to help boost guideline-based standard-of-care for optimal utilisation of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.
The first stage will assess the impact of AI-enabled in vitro diagnostic solutions to optimise use of therapeutics in CKD under current standard of care protocols.
Based on study outcomes, a multi-centre, randomised controlled trial will be initiated to evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalaemia.
Read more: http://www.pharmatimes.com/news/az_partners_with_renalytixai_in_chronic_disease_pact_1347240
In the first stage in the partnership, the companies will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to look at further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System.
The goal of this is to help boost guideline-based standard-of-care for optimal utilisation of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.
The first stage will assess the impact of AI-enabled in vitro diagnostic solutions to optimise use of therapeutics in CKD under current standard of care protocols.
Based on study outcomes, a multi-centre, randomised controlled trial will be initiated to evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalaemia.
Read more: http://www.pharmatimes.com/news/az_partners_with_renalytixai_in_chronic_disease_pact_1347240
